Fig. 2

Bevacizumab response stratified by the expression level of miR-25. A Bevacizumab conferred significant improvements in PFS for patients with low miR-25 expression (HR: 0.71, 95%CI: 0.54–0.94, Log-rank P = 0.015). B It seemed that bevacizumab conferred improvements in OS for patients with low miR-25 expression though without reaching statistical significance (HR: 0.69, 95%CI: 0.46–1.03, Log-rank P = 0.072). C No significant survival benefits from bevacizumab were observed in patients with high miR-25 expression in terms of PFS (HR: 0.75, 95%CI: 0.29–2.00, Log-rank P = 0.570). D No significant survival benefits from bevacizumab were observed in patients with high miR-25 expression in terms of OS (HR: 1.38, 95%CI: 0.13–14.23, Log-rank P = 0.789)